Chemotherapy-Induced Peripheral Neurotoxicity as A Risk Factor for Poor Sleep Quality in Breast Cancer Survivors Treated with Docetaxel.
Chemotherapy-Induced Peripheral Neurotoxicity as A Risk Factor for Poor Sleep Quality in Breast Cancer Survivors Treated with Docetaxel.
复制标题
DOI：
10.4103/apjon.apjon_51_20
复制
发表时间：
2021-01
影响因子：
1.8
通讯作者：
Wang YJ
中科院分区：
文献类型：
--
作者：
Chan YN;Jheng YW;Wang YJ
本研究的目的是探讨睡眠质量，并确定化疗诱导的周围神经毒性是否是接受多西他赛治疗的乳腺癌幸存者睡眠质量差的风险因素。横断面研究的次要数据分析。使用信息表收集样本特征。独立变量包括医院焦虑和抑郁量表（HADS），患者神经毒性问卷（PNQ）和识别疼痛问卷（ID疼痛）。睡眠质量评估采用匹兹堡睡眠质量指数（PSQI）。我们进行了描述性分析和简单logistic回归。共有98名参与者。超过60%的人报告睡眠质量差，他们的平均PSQI得分为7.54 ± 4.45。主观睡眠质量差（1.37 ± 0.88）和睡眠时间短（1.37 ± 1.08）是主要问题。此外，睡眠质量差的重要危险因素是慢性疾病（OR = 2.753，P = 0.041），焦虑（OR = 7.714，P = 0.009），神经病理性疼痛（OR = 11.261，P = 0.022）、感觉神经病变（OR = 2.529，P = 0.032）、运动神经病变（OR = 3.781，P = 0.002）和正在接受化疗（OR = 2.593，P = 0.027）。部分存活者接受的靶向治疗是保护因素（OR = 0.351，P = 0.015）。我们发现多西他赛治疗的乳腺癌幸存者睡眠质量差的发生率很高。结果表明，除了临床特征和心理不适外，化疗引起的周围神经毒性是睡眠质量差的重要危险因素。
The purpose of this study was to explore sleep quality and to determine whether chemotherapy-induced peripheral neurotoxicity is a risk factor for poor sleep quality in breast cancer survivors who receive docetaxel treatment. Secondary data analysis from a cross-sectional study. Sample characteristics were collected using an information sheet. Independent variables included the Hospital Anxiety and Depression Scale (HADS), the Patient Neurotoxicity Questionnaire (PNQ), and the Identification Pain Questionnaire (ID pain). Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). We performed descriptive analyses and simple logistic regression. A total of 98 participants were included. More than 60% of them reported poor sleep quality, with their average PSQI score being 7.54 ± 4.45. Poor subjective sleep quality (1.37 ± 0.88) and short sleep duration (1.37 ± 1.08) were their main problems. In addition, significant risk factors for poor sleep quality were chronic illness (odds ratio [OR] = 2.753, P = 0.041), anxiety (OR = 7.714, P = 0.009), neuropathic pain (OR = 11.261, P = 0.022), sensory neuropathy (OR = 2.529, P = 0.032), motor neuropathy (OR = 3.781, P = 0.002), and undergoing chemotherapy (OR = 2.593, P = 0.027). Targeted therapy that some survivors received served as a protective factor (OR = 0.351, P = 0.015). We found a high prevalence of poor sleep quality in breast cancer survivors treated with docetaxel. The results indicated that, in addition to clinical characteristics and psychological discomfort, chemotherapy-induced peripheral neurotoxicity is a significant risk factor for poor sleep quality.
登录
查看更多内容
影响因子：
3.1
作者：
Desai, Krupali;Mao, Jun J.;Su, Irene;DeMichele, Angela;Li, Qing;Xie, Sharon X.;Gehrman, Philip R.
通讯作者：
Gehrman, Philip R.
影响因子：
3.4
作者：
Medic G;Wille M;Hemels ME
通讯作者：
Hemels ME
影响因子：
3.1
作者：
Sanford, Stacy D.;Wagner, Lynne I.;Cella, David
通讯作者：
Cella, David
影响因子：
2.6
作者：
Hong, J. S.;Tian, J.;Wu, L. H.
通讯作者：
Wu, L. H.
患有和没有三阴性乳腺癌（TNBC）的黑乳腺癌幸存者的健康相关生活质量。
影响因子：
3.8
作者：
Vadaparampil ST;Christie J;Donovan KA;Kim J;Augusto B;Kasting ML;Holt CL;Ashing K;Halbert CH;Pal T
通讯作者：
Pal T